CRISPR Therapeutics AG public offering of an aggregate 4,887,500 common shares

On 20 November 2019, CRISPR Therapeutics AG launched its public offering of an aggregate 4,887,500 common shares on Nasdaq raising approximately USD 315.2 million. CRISPR Therapeutics is a leading gene editing company based in Zug, Switzerland, focusing on developing transformative gene-based medicines for serious diseases based on its proprietary CRISPR/Cas9 technology.

Jacobs Holding completes the placement of Barry Callebaut Shares

Jacobs Holding AG successfully placed 550,000 shares (approx. 10%) in Barry Callebaut AG by way of an accelerated bookbuilding process and a simultaneous private placement. Jacobs Holding thus diversified its portfolio while remaining Barry Callebaut’s reference shareholder with a stake of approximately 40%. Jacobs Holding is an investment company founded by entrepreneur Klaus J. Jacobs. The only economic beneficiary of Jacobs Holding is the Jacobs Foundation, one of the world’s leading charitable foundations for the promotion of development opportunities for children and young people.

Canton of Geneva issued a Green Bond

On 28 November 2019 the Canton of Geneva issued green bonds listed on the SIX Swiss Exchange in an aggregate amount of CHF 660 million. The issuance was made according to the Green Bond Principles published by the International Capital Market Association, and divided into three respective tranches of CHF 175 million with a maturity in 2028, CHF 200 million with a maturity in 2039 and CHF 285 million with a maturity in 2032.

WisdomTree Issuer X Limited launched one of the world’s first crypto index ETP listed on a regulated stock exchange

On 3 December 2019, WisdomTree Issuer X Limited was recognized by the SIX Swiss Exchange as a new Exchange Traded Product (ETP) issuer to its trading segment and, launched one of the world’s first crypto index ETP listed on a regulated stock exchange. The ETP is investing in Bitcoin.

Kuros Biosciences completes rights offering

On 6 December 2019, Kuros Biosciences, a life science company focusing on the development and marketing of orthobiologics, completed a capital increase by way of a rights offering to its shareholders. 36.3% of the shareholders of Kuros Biosciences exercised their subscription rights in the rights offering. 2,818,718 of the remaining shares not subscribed were preferably allocated to Optiverder B.V. and further remaining shares were placed in the market. The offer price was set at CHF 1.95 per share.

SCHMOLZ + BICKENBACH AG launches its rights offering

SCHMOLZ + BICKENBACH’s rights offering that launched on 10 December 2019. On 2 December 2019, the extraordinary shareholders’ meeting of SCHMOLZ + BICKENBACH approved a capital increase of at least CHF 325 million through the issuance of up to 2,953,125,000 new registered shares, and a simultaneous reduction of the nominal value of the existing registered shares from CHF 0.50 per share to the level of the offer price, which is expected to be one of CHF 0.20, CHF 0.25 or CHF 0.30 per new share. The gross proceeds from the capital increase are envisaged to be at least CHF 325 million. The listing and first day of trading of the new registered shares on SIX Swiss Exchange are expected to take place on 9 January 2020.

Seminar: 17th Annual Zurich Stock Corporation Conference (17. Zürcher Aktienrechtstagung)

3 March 2020, Zurich

https://www.eiz.uzh.ch/EIZ/web/eiz/event.aspx?WPParams=43A9B2A7C6D4E0E8AAB08D92A7929F

Seminar: 10th Annual Zurich Conference on Responsibility in Corporate Law (10. Zürcher Tagung zur Verantwortlichkeit im Unternehmensrecht)

11 February 2020, Zurich

https://www.eiz.uzh.ch/EIZ/web/eiz/event.aspx?WPParams=43A9B2A7C6D4E0E8AAB08D92A7929E

Vortragsreihe am Mittag: Corporate Responsibility: Why the Stakeholder Model is Doomed to Fail and how Good Corporations Should Behave

28 February 2020, Zurich

https://www.eiz.uzh.ch/EIZ/web/eiz/event.aspx?WPParams=43A9B2A7C6D4E0E8AAB08D92A792A6

Rights Offering of Kuros Biosciences

On 6 December 2019, Kuros Biosciences, a life science company focusing on the development and marketing of orthobiologics, completed a capital increase by way of a rights offering to its shareholders. 36.3% of the shareholders of Kuros Biosciences exercised their subscription rights in the rights offering. 2,818,718 of the remaining shares not subscribed were preferably allocated to Optiverder B.V. and further remaining shares were placed in the market. The offer price was set at CHF 1.95 per share.